Teva, the patent suit expert, achieves the first ‘winning’ against AZ in Korea
Teva, which grew its body through patent lawsuits in the U.S., announced the first ‘winning’ of a lawsuit in Korea.
Teva-Handok, jointly established in Korea by Teva and Handok, succeeded in avoiding 3 formulation patents of Symbicort Turbuhaler(AstraZeneca) by the defensive confirmation trial f...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
